Modality
Degrader
MOA
BCMA ADC
Target
SOS1
Pathway
Incretin
SCLC
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
~Aug 2019
→ ~Nov 2020
Phase 3
~Feb 2021
→ ~May 2022
NDA/BLA
~Aug 2022
→ ~Nov 2023
Approved
Feb 2024
→ Nov 2028
ApprovedCurrent
NCT08163066
1,225 pts·SCLC
2024-02→2028-11·Completed
1,225 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2028-11-222.6y awayPh3 Readout· SCLC
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Complet…
Catalysts
Ph3 Readout
2028-11-22 · 2.6y away
SCLC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08163066 | Approved | SCLC | Completed | 1225 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 | |
| Zanurapivir | Immunocore | Phase 1 | SOS1 |